Cardlytics Inc (NASDAQ:CDLX) CFO David Thomas Evans sold 3,000 shares of the company’s stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $85.02, for a total transaction of $255,060.00. Following the transaction, the chief financial officer now owns 22,236 shares of the company’s stock, valued at $1,890,504.72. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

David Thomas Evans also recently made the following trade(s):

  • On Thursday, January 2nd, David Thomas Evans sold 22,000 shares of Cardlytics stock. The shares were sold at an average price of $61.36, for a total transaction of $1,349,920.00.
  • On Monday, December 16th, David Thomas Evans sold 3,000 shares of Cardlytics stock. The shares were sold at an average price of $57.00, for a total transaction of $171,000.00.
  • On Tuesday, December 3rd, David Thomas Evans sold 22,000 shares of Cardlytics stock. The shares were sold at an average price of $63.70, for a total transaction of $1,401,400.00.
  • On Tuesday, November 26th, David Thomas Evans sold 21,281 shares of Cardlytics stock. The shares were sold at an average price of $55.98, for a total transaction of $1,191,310.38.
  • On Friday, November 15th, David Thomas Evans sold 3,000 shares of Cardlytics stock. The shares were sold at an average price of $57.12, for a total transaction of $171,360.00.
  • On Wednesday, November 13th, David Thomas Evans sold 12,000 shares of Cardlytics stock. The shares were sold at an average price of $51.69, for a total transaction of $620,280.00.
  • On Friday, November 1st, David Thomas Evans sold 5,000 shares of Cardlytics stock. The shares were sold at an average price of $40.98, for a total transaction of $204,900.00.
  • On Tuesday, October 29th, David Thomas Evans sold 6,906 shares of Cardlytics stock. The shares were sold at an average price of $41.91, for a total transaction of $289,430.46.

CDLX opened at $82.99 on Thursday. The firm’s 50-day simple moving average is $62.93 and its 200-day simple moving average is $42.66. Cardlytics Inc has a twelve month low of $14.14 and a twelve month high of $90.50. The firm has a market cap of $2.00 billion, a price-to-earnings ratio of -38.78 and a beta of 1.72.

Cardlytics (NASDAQ:CDLX) last posted its earnings results on Tuesday, November 12th. The company reported $0.03 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.28) by $0.31. The business had revenue of $56.42 million for the quarter, compared to analyst estimates of $50.02 million. Cardlytics had a negative net margin of 17.01% and a negative return on equity of 44.53%. The firm’s quarterly revenue was up 63.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.15) EPS. As a group, sell-side analysts predict that Cardlytics Inc will post -1.02 EPS for the current fiscal year.

Several equities research analysts have issued reports on CDLX shares. Bank of America reissued an “average” rating and issued a $100.00 price target on shares of Cardlytics in a report on Tuesday. Zacks Investment Research lowered shares of Cardlytics from a “buy” rating to a “hold” rating in a report on Thursday, December 5th. JPMorgan Chase & Co. lowered shares of Cardlytics from an “overweight” rating to a “neutral” rating and set a $58.00 price target on the stock. in a report on Thursday, November 14th. They noted that the move was a valuation call. Craig Hallum boosted their price target on shares of Cardlytics from $75.00 to $100.00 and gave the company a “buy” rating in a report on Tuesday. Finally, Raymond James lowered shares of Cardlytics from an “outperform” rating to a “market perform” rating in a report on Wednesday. They noted that the move was a valuation call. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $62.14.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. California State Teachers Retirement System lifted its position in Cardlytics by 2.4% during the 3rd quarter. California State Teachers Retirement System now owns 21,444 shares of the company’s stock worth $719,000 after buying an additional 510 shares in the last quarter. Tower Research Capital LLC TRC lifted its position in Cardlytics by 35.0% during the 3rd quarter. Tower Research Capital LLC TRC now owns 4,079 shares of the company’s stock worth $137,000 after buying an additional 1,057 shares in the last quarter. Bank of Montreal Can lifted its position in Cardlytics by 16,371.4% during the 2nd quarter. Bank of Montreal Can now owns 1,153 shares of the company’s stock worth $30,000 after buying an additional 1,146 shares in the last quarter. Rhumbline Advisers lifted its position in Cardlytics by 9.0% during the 3rd quarter. Rhumbline Advisers now owns 14,356 shares of the company’s stock worth $481,000 after buying an additional 1,180 shares in the last quarter. Finally, First Mercantile Trust Co. lifted its position in Cardlytics by 24.9% during the 3rd quarter. First Mercantile Trust Co. now owns 13,734 shares of the company’s stock worth $460,000 after buying an additional 2,738 shares in the last quarter. Institutional investors and hedge funds own 93.17% of the company’s stock.

Cardlytics Company Profile

Cardlytics, Inc operates a purchase intelligence platform in the United States and the United Kingdom. It operates in two segments, Cardlytics Direct and Other Platform Solutions. The company's platform is the Cardlytics Direct solution, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels.

Read More: Cost of Debt

Insider Buying and Selling by Quarter for Cardlytics (NASDAQ:CDLX)

Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.